Physician profile

Richard Fuller

Adult Medicine · Brookfield, WI

NPI 1306841002

$712.48

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$237.61

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bioventus LLC $316.47 2021-2024 Supartz Fx Sodium Hyaluronate, Supartz Fx Sodium Hyaluronate
Fidia Pharma USA INC. $89.15 2022-2024 Hyalgan
Horizon Therapeutics Plc $78.02 2021
Ferring Pharmaceuticals INC. $71.93 2021-2023 Euflexxa
Depuy Synthes Sales INC. $47.95 2021-2022
Averitas Pharma INC. $37.66 2023-2024 Qutenza
Zimmer Biomet Holdings, INC. $37.48 2022
Grt US Holding, INC. $18.49 2021
Avanos Medical $15.33 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Richard Fuller

$712.48

in general payments reported 2019-2025

Years
2021-2024
Top company
Bioventus LLC

https://glasscript.com/doctor/456590/richard-fuller

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.